Articles

The Hidden Risk in Pharma Pricing: When Poor Governance Undermines Commercial Ambition 

10/08/2026

Pricing strategies rarely fail because of one decision. More often, price potential is gradually eroded by smaller local concessions made under payer pressure1. Poor pricing governance is often the root cause. If teams are unclear on decision rights, information sharing or when payer scrutiny must be escalated, local pricing decisions can drift from global strategy. 

Global teams may have clear pricing strategy and evidence narrative. Yet this ambition is harder to achieve if local affiliates have limited input on market feasibility, or limited guidance on negotiation guardrails and alternative commercial terms that they can propose.  

Governance therefore must protect price ambition without slowing local access. 


How weak governance impacts global pricing strategy 

Poor pricing governance can create a gap between the price ambition agreed globally and what is achieved locally. Closing this gap requires organisations to identify where governance shortcomings arise, understand their root causes, and implement targeted measures to address them. 

Global teams may define a target price corridor, floor price, launch sequence and evidence narrative. Local affiliates, however, negotiate with payers under time constraints. If they do not know what concession they can propose or accept, when global approval is needed or how payer feedback should be escalated, they are left to make judgement calls. 

Not addressing these issues creates two risks. A local team may accept a concession that appears pragmatic in one market but weakens price expectations elsewhere, particularly where international reference pricing creates cross-country consequences2. Conversely, a global team may reject a local proposal late because it falls below a threshold the affiliate did not know existed. 

Confidentiality is also central. Floor prices, net price assumptions and deal logic should be limited to a pre-defined group. If shared too widely, even internally, they can undermine the overall pricing strategy. If held too tightly, affiliates may negotiate without understanding the boundaries they need to protect. 

This is not usually a failure of individual teams. It is a capability and governance gap. Good governance allows local teams to move at pace without risking the global pricing ambition. 


Building governance through alignment, not process alone 

Pricing strategy is often decided globally before local teams can test feasibility in their markets. This can create friction later, when affiliates find that the global ambition does not fully reflect local affordability barriers, evidence expectations or payer priorities. 

Bringing global teams and priority affiliates together earlier on, can help identify what is workable, where risks may emerge and what support local teams need. This means creating a structured route for local input, so global strategy is more pragmatic and affiliates feel empowered to operate within its boundaries.  


Matching the governance gap to the right intervention 

Governance gaps are unique to each organisation. Some need clearer decision rights, others need stronger capability, tighter confidentiality rules, or a process that better reflects existing ways of working. Here we summarise some common challenges and potential ways of addressing them:

Governance challenge Relevant support What it helps solve Watch-out 
Local / global misalignment Cross-functional workshops, regular affiliate input sessions Ensures local constraints and market-specific negotiation barriers are communicated upwards and incorporated into global strategy / assumptions Needs clear outputs and escalation routes 
Inconsistent / unclear pricing decisions Governance framework, decision matrix Clarifies thresholds, alternative commercial terms, defines roles and timing Must have clear owners and approval processes 
Confidential price risk Floor price rules, net price access rules, governance playbook Protects sensitive assumptions while giving affiliates usable guidance Inflexible frameworks can slow negotiations. Requires robust scenario planning and decision-trees 
Limited internal awareness Targeted pricing training, capability-building  Builds common understanding across pricing, market access, HEOR, medical, commercial and affiliates Most valuable asset-specific 
Slow approvals Process redesign, streamlined templates, role clarity Helps teams respond at payer speed, while reinforcing guardrails Avoid over-engineering processes to preserve agility in negotiations 

Refreshing your pricing governance approach should help teams better protect value globally. A strong process should answer three practical questions: 

  • Do affiliates feel empowered to implement different negotiation scenarios , and are fully aligned on how it fits in the global strategy? 
  • Can global teams effectively influence ongoing negotiations in a timely manner, if needed? 
  • Is sensitive pricing information sufficiently protected, without leaving affiliates under-informed? 

If you think your pricing governance approach needs a refresh, Remap can help companies in identifying where pricing governance is creating commercial risk, aligning internal stakeholders, designing pragmatic local / global price governance processes and building capability through targeted training3-5


References

  1. Remap Consulting, Barnes H. Why Pricing Strategy Must Start Earlier: Linking Evidence, Access, and Value from Day One https://remapconsulting.com/hta/early-pricing-strategy/ 
  2. Remuzat C, Urbinati D, Mzoughi O, El Hammi E, Belgaied W, Toumi M. Overview of external reference pricing systems in Europe. J Mark Access Health Policy. 2015;3 
  3. Remap Consulting. Payer Insights. https://remapconsulting.com/services/pricing/payer-insights/ 
  4. Remap Consulting. HTA & Payer Early Dialogue. https://remapconsulting.com/services/launch/hta-payer-early-dialogue/ 
  5. Remap Consulting. Training. https://remapconsulting.com/services/training/ 

Frequently Asked Questions

What is pricing governance in pharma? 

Pricing governance is the process that defines how pricing decisions are made, reviewed and escalated across global and local teams. It sets out who can approve pricing decisions, what information can be shared, how payer feedback should be handled and how confidential pricing assumptions should be protected 

Why does pricing governance matter? 

Payer negotiations are often time-sensitive. Local affiliates need enough guidance to respond quickly, but their decisions must still align with global price ambition and cross-country price defence strategy. Effective pricing governance helps affiliates understand what they can propose or accept, when global input is needed and how to avoid concessions that could create wider pricing risk. For example, an affiliate may accept a concession that appears pragmatic locally but weakens price corridor in other markets. Alternatively, global teams may reject a local proposal late in the process, often negatively impacting access, because it falls below a threshold the affiliate were not aligned on. 

How should companies manage confidential pricing assumptions internally? 

Confidential pricing assumptions, such as floor prices, net price assumptions and deal logic, should be limited to a pre-defined group. However, affiliates still need enough context and global support to negotiate with payers optimally. The aim is to protect sensitive information while giving local teams clear guidance on negotiation boundaries and escalation triggers. 

How can companies improve pricing governance? 

Companies can improve pricing governance by first understanding what is and is not working in the current process. Cross-functional workshops can identify pain points, governance updates can align the process with company ways of working, and targeted training can help global and local teams implement the updated process consistently.

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.